natgillin/translations-raw huggingface dataset:
the C-terminal second fragment comprises a second proximal N-terminal end within a second repeat portion, said second repeat portion including a portion of repeat portion I of toxin B (amino acids 1897-1926 of SEQ ID NO:2) or repeat portion II of toxin B (amino acids 2028-2057 of SEQ ID NO:2); and wherein the first proximal C-terminal end of the N-terminal first fragment and the second proximal N-terminal end of the C-terminal second fragment are joined by 5 to 0 amino acids such that B-solenoid structure is maintained through the junction between the two fragments, 
proksimalni kraj drugog fragmenta se nalazi unutar drugog ponavljanog dijela; i gdje su prvi fragment i drugi fragment razdvojeni s manje od ili točno 5 aminokiselina u primarnoj strukturi, gdje polipeptid dovodi do pojave protutijela koja neutraliziraju toksin A i toksin B, te gdje su prvi ponavljani dio i drugi ponavljani dio imaju između sebe više od 50% istovjetnog slijeda.
Use of a composition comprising: 
Uporaba sastava koja obuhvaća:
Even more preferred is the combination of an M3 antagonist of the invention with cilomilast and the combination of an M3 antagonist of the invention with roflumilast. 
Osobito poželjno utjelovljenje predmetnog izuma je kombinacija M3 antagonista sukladno predmetnom izumu s kortikosteroidom odabranim između sljedećeg: budesonid, beklometazon dipropionat, mometazon furoat, ciklesonid 1 flutikazon propionat.
When the carrier serves as a diluent, it may be a solid, lyophilized solid or paste, semi-solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing for example up to 10% by weight of the active compound. 
Kada je podloga razrjeđivač, to može biti krutina, liofilizirana krutina ili pasta, polukrutina, ili tekući materijal koji djeluje kao vehikulum, ili može biti u obliku tableta, pilula, prašaka, lozengeta, ljekovitih napitaka, suspenzija, emulzija, otopina, sirupa, aerosola (kao krutina ili u tekućem mediju), ili mast koja primjerice sadrži do 10 %, težinski, aktivnog spoja.
is selected from the group consisting of an optionally substituted alkylene, an optionally substituted alkenylene, an optionally substituted heteroalkylene and an optionally substituted heteroalkenylene; 
L* je odabran iz skupine koju čine po izboru supstituiran alkilen, po izboru supstituiran alkenilen, po izboru supstituiran heteroalkilen i po izboru supstituiran heteroalkenilen;
separating the trans-(-)-A9-tetrahydrocannabinol and/or the trans-(+)-A9-tetrahydrocannabinol from the alcoholic-caustic phase; and 
separaciju trans-(-)-A9-tetrahidrokanabinola i/ili trans-(+)-A9-tetrahidrokanabinola od alkoholno-kaustične faze; i
A compound for use in prophylactically treating a patient at risk of thrombocytopenia, comprising administering to said patient a prophylactically effective amount of a compound which comprises (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, wherein X10 is selected from the group consisting of sarcosine or B-alanine, wherein 2-nal is B-(2-naphthyl)alanine, and wherein said compound is covalently attached to a hydrophilic polymer. 
Spoj za uporabu u profilaktičkom tretmanu pacijenta koji je u opasnosti od trombocitopenije, koji obuhvata davanje navedenom pacijentu profilaktički učinkovite količine spoja koji sadrži (H-IEGPTLRQ(2-Nal)LAARX10)2KNH2, pri čemu je X10 odabran iz skupine koju čine sarkozin ili B-alanin, pri čemu 2-Nal je B-(2-naftil) alanin, i pri čemu je navedeni spoj kovalentno vezan za hidrofilni polimer.
Capsule according to any of the preceding claims, wherein the fibrous and/or paperlike material covers at least part of one of the walls of the capsule, for example the third wall (216B; 319; 519). Capsule according to any of the preceding claims, wherein the sealing member (216B; 319; 519) has a laminate structure. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu najmanje jedan ispupčeni dio (127) je plastično promjenljivog oblika. Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je ispupčeni dio (127) napravljen od istog materijala kao čašica. Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je ispupčeni dio (127) izveden iz jednog dijela sa čašicom.
• R2 represents a benzene ring, the ring being optionally substituted 1 to 4 substituents selected from a C1-3 alkyl group, a halogen atom, a hydroxyl group or a C1-2 alkoxy group; and 
R2 predstavlja benzenski prsten, izborno supstituiran s 1 do 4 supstituenta, koje se bira između Ci. alkilne skupine, atoma halogena, hidroksilne skupine ili C, > alkoksi skupine; 1
The veterinary or agricultural composition according to claim 25, wherein the macrocyclic lactone is an avermectin or a milbemycin. 
Veterinarski ili agrikulturni sastav prema zahtjevu 25, naznačen time, da makrociklički lakton je avermektin ili milbemicin.
An IL-18BP or a viral IL-18BP, may thus be fused to another protein, polypeptide or the like, e.g., an immunoglobulin or a fragment thereof. 
IL-18BP ili viralni IL-18BP mogu tako biti fuzionirani s drugim proteinom, polipeptidom i slično, pr. imunoglobulinom ili njegovim fragmentom.
the dosage unit (b) is a bottle having a capacity of about 7 ml, containing a pharmaceutical composition composed of 5 mg of tacrolimus dissolved in 1 ml of solvent composed of 200 mg of polyoxyethylenated hydrogenated castor oil (HCO-60) and ethanol q.s. to 1 ml; 
je jedinica doziranja (b) bočica koja ima zapreminu od oko 7 ml, koja sadrži farmaceutski sastav sastavljen od 5 mg takrolimusa otopljenog u 1 ml otapala, sastavljenog od 200 mg polioksietiliranog hidriranog ricinusovog ulja (HCO-60) i etanola dopunjenog do 1 ml;
a further stringer element (32) interposed between said lateral upright elements (21, 22) in such a way to define, together with part of one of said upright elements (21) and to said brace element (4), a structure with a substantially triangular geometry; and 
- < dodatni element za pojačanje (32) umetnut između navedenih bočnih okomitih elemenata (21, 22) na takav način da tvori, zajedno s dijelom jednog od navedenih okomitih elemenata (21) 1 dijelom navedenog dijagonalnog elementa (4), strukturu koja u osnovi ima trokutnu geometriju; te
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fludioxonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Thus, the piercing of the container closure 22 is conducted automatically when pressure is applied to the pressure chamber 8. 
Tako se, dakle, probijanje pokrova spremnika 22 vrši automatski kad pritisak djeluje na tlačnu komoru 8.
The results obtained show that all the milk samples contain dimethylsulphide. 
Dobiveni rezultati su pokazali da svi uzorci mlijeka sadržavaju dimetilsulfid.
The pharmaceutical combinations according to the invention may contain (a) and (b) in the case of roflumilast, for example, in a ratio by weight (b):(a) ranging from 1: 10 to 300: 1, preferably from 1: 5 to 200: 1, preferably 1: 3 to 150: 1, more preferably from 1: 2 to 100: 1. 
Farmaceutske kombinacije sukladno predmetnom izumu mogu sadržavati (a) i (b) u slučaju budesonida, na primjer u težinskom omjeru (b):(a) u rasponu od 1:10 do 50:10, poželjno od 1:5 do 10:1, poželjno od 1:4 do 5:1, a najpoželjnije od 1:2 do 2:1.
A compound according to claim 25, wherein the disease, disorder, or medical condition is selected from the group consisting of: anxiety, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, and neuroinflammation. 
Spoj prema zahtjevu 11, naznačen time da je bolest, poremećaj ili medicinsko stanje izabrano iz skupine koju čine: tjeskoba, bol, poremećaji spavanja, poremećaji prehrane, upala, poremećaji kretanja, gubitak tjelesne težine zbog HIV-a, unutrašnja ozljeda glave, moždani udar, Alzheimerova bolest, epilepsija, Touretteov sindrom, Niemann-Pickova bolest, Parkinsonova bolest, Huntingtonova koreja, optički neuritis, autoimuni uveitis, simptomi odvikavanja od narkotika, mučnina, povraćanje, seksualna disfunkcija, post traumatski stresni poremećaj, cerebralni vazospazam, glaukom, sindrom iritabilnog crijeva, upalna bolest crijeva, imunosupresija, gastroezofagusna refluksna bolest, paralitički ileus, sekretorni proljev, čir na želucu, reumatoidni artritis, neželjena trudnoća, hipertenzija, karcinom, hepatitis, alergijska bolest dišnih putova, autoimuni dijabetes, kronični pruritis, te neuroupala.
A pharmaceutical composition comprising a compound of formula (I): wherein: 
Spoj s formulom (I): [image] pri čemu:
The compound for the use of any of claims 1 to 8, wherein at least a portion of the compound is present as an amorphous form having an X-ray diffraction pattern (CuKa) with a halo peak at approximately 13.5° 2θ, substantially as shown in FIG. 
Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je u najmanju ruku dio spoja prisutan kao amorfni oblik s uzorkom difrakcije rendgenskih zraka (CuKa) s maksimumom hala na otprilike 13,5° 2θ, uglavnom kao što je prikazano na SL.
the VH polypeptide amino acid sequence as set forth as SEQ ID NO:70 and the VL polypeptide amino acid sequence as set forth as SEQ ID NO:81. 
Protutijelo protiv sklerostina, naznačeno time, da obuhvaća polipeptidnu sekvencu varijabilnog područja jakog lanca, koja sadrži SEQ ID NO: 70 i polipeptidnu sekvencu varijabilnog područja slabog lanca, koja sadrži SEQ ID NO: 81.
The cellulose reactive agent can be glyoxal, glutaraldehyde, furan dialdehyde, 2-hydroxyadipaldehyde, succinaldehyde, dialdehyde starch, diepoxy compounds, or combinations thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je sredstvo koje reagira s celulozom glioksal, glutaraldehid, furan-dialdehid, 2-hidroksiadipaldehid, sukcinaldehid, dialdehid škroba, diepoksidni spojevi, ili njihove kombinacije.
A kit comprising: a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, or a cell according to claim 6, in solution or in lyophilized form; and 
Komplet koji sadrži: posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanicu u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T limfocit u skladu s patentnim zahtjevom 11, u otopini ili u liofiliziranom obliku;
Ulipristal acetate (17a-acetoxy-11B-[4- N, N -dimethylamino-phenyl)-19-norpregna- 4, 9-diene-3, 20-dione) or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 1 for a further use in preventing or treating anemia in said patient. 
Ulipristal acetat (17a-acetoksi-115-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice,
Use according to claim 13 wherein the disorder is multiple sclerosis (MS) or experimental autoimmune encephalomyelitis (EAE). 
Uporaba prema zahtjevu 11 naznačena time da poremećaj je multipla skleroza (MS) ili eksperimentalni autoimuni encefalomijelitis (EAE).
Use of a compound according to claim 16 or a composition according to any one of claims 17 to 21 and 24 for the manufacture of a medicament for treating a disorder of the central nervous system; damage to the central nervous system; a cardiovascular disorder; a gastrointestinal disorder; diabetes insipidus, or sleep apnea. 
Uporaba spoja u skladu s bilo kojim zahtjevom 1 do 11, naznačena time, da se koristi za izradu lijeka za liječenje poremećaja središnjeg živčanog sustava; oštećenja središnjeg živčanog sustava; kardiovaskularnog poremećaja; gastrointestinalnog poremećaja; dijabetesa insipidusa ili apneje spavanja.
The method of any of Claims 1-4, wherein said RNA composition is characterized by at least one of the following: 
Obrađeni sastav ribonukleinske kiseline prema bilo kojem od zahtjeva 1 ili 2, naznačena time, da je navedena ssRNA ili mRNA karakterizirana najmanje jednim od sljedećeg:
The pharmaceutical composition of (a), further comprising a second therapeutic agent selected from the group consisting of a HCV antiviral agent, an immunomodulator, and an anti-infective agent. 
Farmaceutska kompozicija prema patentnom zahtjevu 10, naznačena time što dalje sadrži drugo terapeutsko sredstvo izabrano iz grupe koju čine HCV antivirusno sredstvo, imunomodulator i anti-infektivno sredstvo.
A method according to claim 4, in which, in the case of an electric device arranged to consume electric energy, the one or more requests result in the electric device being disconnected from said electricity distribution network during the associated time interval, and in the case of an electric device arranged to provide electric energy, the one or more requests results in the electric device being connected to the electricity distribution network during the associated time interval. 
Postupak prema zahtjevu 4, naznačen time da, u slučaju da je električni uređaj (208) predviđen za potrošnju električne energije, jedan ili više zahtjeva rezultira sa time da je električni uređaj (208) isključen iz navedene mreže za distribuciju električne energije tijekom odgovarajućeg vremenskog intervala, te u slučaju da je električni uređaj (208) predviđen za predavanje električne energije, jedan ili više zahtjeva rezultira sa time da se električni uređaj (208) spaja na mrežu za distribuciju električne energije tijekom odgovarajućeg vremenskog intervala.
passage through membranes or molecular sieves with cut-off of 300,000 Daltons; 
- prolaza kroz membrane ili molekulska sita granične veličine 300000 Daltona;
Still Other Examples of Embodiments of the Invention Include 
Broj objave europskog patenta:
from 10% to 80% by weight of a mineral component based on silica and/or alumina, and 
(b) od 10 do 75% po masi mineralne komponente na bazi silicijevog dioksida 1 / ili aluminijevog oksida, 1
The peptide according to any one of claims 1 to 3 or an activated cytotoxic T lymphocyte according to claim 10 for use according to claim 11 in the form of a cancer vaccine. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanica u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11 za upotrebu u skladu s patentnim zahtjevom 12 u obliku cjepiva protiv karcinoma.
is aryl, C3-C12 cycloalkyl or heterocyclyl, wherein aryl, C3-C12 cycloalkyl or heterocyclyl is each optionally substituted by one or more hydroxy, oxo, halogen, amino, aminoalkyl, alkyl (optionally substituted at one or more positions by halogen, hydroxy or lower Alkoxy), alkoxy (optionally substituted at one or more positions by halogen or hydroxy), carboxy, carbonylalkoxy, carbamoyl, carbamoylalkyl, aminosulfonyl,lower alkyl-aminosulfonyl, aryl, aryloxy, arylalkoxy or heterocyclyl; 
je aril, C3-C12 cikloalkil ili heterociklil, pri čemu je svaki od aril, C3-C12 cikloalkil ili heterociklil po izboru supstituiran s jednim ili više hidroksi, okso, halogen, amino, aminoalkil, alkil (po izboru supstituiranim u jednom ili više položaja s halogenom, hidroksi ili nižim alkoksi), alkoksi (po izboru supstituiranim u jednom ili više položaja s halogenom ili hidroksi), karboksi, karbonilalkoksi, karbamoil, karbamoilalkil, aminosulfonil, niži alkil-aminosulfonil, aril, ariloksi, arilalkoksi ili heterociklil;
According to a beneficial embodiment of the invention, the largest length in lateral direction in solid base material is less than 100% in particular less than 90% and more in particular less than 70% of the bottom fin chord. 
Lopatica vjetroturbine prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da sadrži 2 peraje i bazu gdje je najveća dužina u bočnom smjeru u čvrstoj bazi manja od 100% naročito manja od 90% 1 više naročito manja od 70% donjeg dijela tetive peraja.
measuring at said remote location the time interval between the occurrence of said relay time stamp signal and the occurrence of a reference point in the wiring phase voltage of said remote location. 
- < mjerenje na spomenutoj udaljenoj lokaciji vremenskog intervala između pojavljivanja spomenutog relejnog vremenskog otisnutog signala i pojavljivanja referentne točke u faznom naponu vodiča spomenute udaljene lokacije.
Thus, on the basis of these tests it was found that, with the laminated disc according to the invention, one can work almost twice as fast as with a conventional finishing disc. 
Na taj načinje na osnovi ovih testova bilo nađeno, da rad s lemeliranim diskom koji je u skladu s ovim izumom, može biti gotovo dvostruko tako brz kao što je s konvencionalnim diskom.
The method of any one of claims 1 to 15, wherein said first tag and said second tag, said first capture element and said second capture element each comprises at least one component independently selected from the group consisting of a polynucleotide, a polypeptide, a peptide nucleic acid, a locked nucleic acid, an oligosaccharide, a polysaccharide, an antibody, an affibody, an antibody mimic, a cell receptor, a ligand, a lipid, biotin, avidin, streptavidin, Extravidin, neutravidin, Traptavidin, a metal, histidine, and any portion of any of these structures. 
Postupak prema bilo kojem od zahtjeva 1 do 15, naznačen time, da svaka od navedene prve oznake i navedene druge oznake, te svaki od navedenog prvog zahvatnog elementa 1 navedenog drugog zahvatnog elementa, obuhvaća najmanje jedan sastojak koji je neovisno odabran iz skupine koju čine: polinukleotid, polipeptid, peptidna nukleinska kiselina, zaključana nukleinska kiselina, oligosaharid, polisaharid, protutijelo, umjetna molekula, imitacija protutijela, stanični receptor, ligand, lipid, biotin, avidin, streptavidin, ekstravidin, neutravidin, traptavidin, metal, histidin i bilo koji dio od bilo koje od navedenih struktura.
In another preferred embodiment, the invention provides derivatives of Formula (Ia) wherein R14 is selected from phenyl and a heterocyclic or heterocycloalkyl group selected from the group consisting of: 1,3-dioxolane, 2,2-dimethyl-1,3-dioxolane, thiophene, 1-methyl-1-morpholino-4-ylethyl, pyrimidine, pyridine, said pyridine optionally substituted with a hydroxy or C1-C6 alkoxy group; pyridinyl-linear or branched C1-C4 alkyl; piperidine, said piperidine optionally substituted with phenyl-C1-C4 alkyl; furane, tetrahydrofurane; 2-tetrahydrofuran-2-ylethyl, pyrrolidine N-carboxylic acid, C1-C4 linear or branched N-alkoxycarbonylpyrrolidin-2-yl; tetrahydropyrane. 
Spoj prema bilo kojem od prethodnih zahtjeva naznačen time da R'' je odabran od heterocikličke ili heterocikloalkilne skupine odabranih iz skupine koju čine: 1,3-dioksolan, 2,2-dimetil-1,3-dioksolan, tiofen, 1-metil-1-morfolino-4-iletil, pirimidin, piridin, navedeni piridin proizvoljno je supstituiran sa hidroksi ili C,-C4 alkoksi skupinom; piridinil-ravni ili razgranati C;-Ca alkil; piperidin, navedeni piperidin proizvoljno je supstituiran sa fenil- C,-C, alkilom; furan, tetrahidrofuran; 2-tetrahidrofuran-2-iletil, pirolidin N-karboksilna kiselina, C,-C, ravni ili razgranati N-alkoksikarbonilpirolidin-2-il; tetrahidopiran.
The filtrate is evaporated to dryness, the residue is stirred for one hour with a mixture of TBME and heptane 7/3 v/v (60 ml), filtered and dried in vacuum. 
Filtrat se evaporira do suhoga, ostatak se miješa tijekom jednog sata sa smjesom TBME i heptana 7/3 v/v (60ml), filtrira se i suši u vakuumu.
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: [wherein R1 represents OR, NRR' which may form a ring or SR, in which R and R' independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms optionally substituted with one or a plurality of alkoxy groups having 1 to 8 carbon atoms, halogen atoms or hydroxyl groups, an aryl group optionally substituted with one or a plurality of alkyl groups having 1 to 8 carbon atoms, alkoxy groups having 1 to 8 carbon atoms or halogen atoms, or a heteroaryl group optionally substituted with one or a plurality of alkyl groups having 1 to 8 carbon atoms, an alkoxy groups having 1 to 8 carbon atoms or a halogen atom, R2 represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, and X1, X2 and X3 are independently CR3 or a nitrogen atom, or X1 is CR3 or a nitrogen atom, and X2 and X3 together form a benzene ring, in which R3 is a hydrogen atom or an alkyl group having 1 to 8 carbon atoms.] 
Ru pri čemu R, predstavlja OR, NRR' koji može tvoriti prsten ili SR, u kojem R i R' neovisno predstavljaju vodikov atom, ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma, halogene atome ili hidroksilne skupine, arilnu skupinu proizvoljno supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogene atome, ili heteroarilnu skupinu po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogeni atom, R, predstavlja vodikov atom, ili ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma, i
Accordingly, in a very preferred embodiment, the caramelised feedstock contains at least 50% by weight of dry matter of brewing adjuncts, including at least 5% caramel by weight of dry matter. 
Prema tome, u vrlo poželjnom ostvarenju, karamelizirana sirovina sadržava najmanje 50% po masi suhe tvari pivarskih dodataka, uključujući najmanje 5% karamele po masi suhe tvari.
The composition according to any one of claims 1 to 10 for the use according to any one of claims 1 to 10, wherein intranasal administration of the composition comprises directed administration of an aerosol of the composition to the nasal epithelium. 
Pripravak prema bilo kojem od zahtjeva 1 do 10, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 10, pri čemu intranazalno davanje pripravka sadrži usmjereno davanje aerosola smjese u nazalni epitel.
The product was obtained by analogy with the method described in example 1(step1.3) and using ethyl 3-amino-3-(cyanomethyl)pyrrolidine-1-carboxylate. 
Produkt sc dobije postupkom analognim onom opisanom u primjeru 1 (korak 1.3), uz upotrcbu ctil-3-amino-3- (cijanometil)pirolidin-1-karboksilata.
10/899641, WO 01/868603 and U.S. patent 6,395,767, employing dosages as set out in the above references. 
10/899641, WO 01/868603 1 U.S. patentu 6,395,767, korištenjem doza kao što su navedene u prethodno navedenoj literaturi.
an (E) or (Z) stereoisomer of any of the above compounds. 
(E) ili (Z) izomer bilo kojeg od gore navedenih spojeva.
Het represents a group of formula 
Het predstavlja skupinu formulo